Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Dantrium IV 20 mg powder for solution for injection

Active Ingredient:
dantrolene sodium
Company:  
Norgine Limited See contact details
ATC code: 
M03CA01
{info_black}
About Medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine.
{info_black}
Last updated on emc: 05 Dec 2022

Below is a text only representation of the Patient Information Leaflet (ePIL).

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on {phone} 0800 198 5000. The product code(s) for this leaflet is: PL 20011/0034.

Dantrium IV 20mg

PACKAGE LEAFLET : INFORMATION FOR THE USER

Dantrium® IV 20 mg

Powder for Solution for Injection

Dantrolene sodium

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Dantrium IV is and what it is used for
2. What you need to know before you are given Dantrium IV
3. How Dantrium IV is given
4. Possible side effects
5. How to store Dantrium IV
6. Contents of the pack and other information

1. What Dantrium IV is and what it is used for

Dantrium IV belongs to the pharmacotherapeutic group of direct-acting muscle relaxants. It is used for the treatment of malignant hyperthermia. The ATC code is M03CA01.

Dantrium IV is a medicine which will be administered to you by a doctor or nurse.

2. What you need to know before you are given Dantrium IV
Do not use Dantrium IV

If you are allergic (hypersensitive) to dantrolene sodium or any of the other ingredients of Dantrium IV (see section 6).

Warnings and precautions

Take special care with Dantrium IV. You will probably have been given Dantrium IV before you read this leaflet. The urgent need for treatment will have been more important than anything else at the time. Before you are given this injection, your doctor will try to find out if you have had a serious reaction to dantrolene sodium or any of the other ingredients of Dantrium IV in the past.

Other medicines and Dantrium IV

Tell your doctor if you are taking, or have recently taken, or might use any other medicine.

The following medicines affect the way Dantrium IV works:

  • drugs for high blood pressure and angina called “calcium channel blockers”
  • muscle relaxants, like vecuronium
  • other intravenous infusion fluids

Pregnancy, breast-feeding and fertility

Tell your doctor if you are pregnant or breastfeeding. Dantrium IV should not be given unless considered essential.

Driving and using machines

For a period of up to 48 hours after you have been given Dantrium IV, your hand and leg muscles may be weak and you may also have a feeling of “light headedness”. If you are affected in this way, do not drive or operate machinery during this time.

Dantrium IV contains sodium

This medicine contains less than 1mmol sodium (23mg) per vial that is to say essentially “sodium free”.

3. How Dantrium IV is given

This injection is given to you by a doctor, into a vein. The dose of Dantrium IV is based on body weight; in most cases, a total dose of up to 10mg may be given for each kilogram of your body weight. However, a total dose of up to 40mg for each kilogram of your body weight may be required in rare cases

If you are given more Dantrium IV than you should

Malignant hyperthermia is an emergency situation where rapid infusion of a high Dantrium IV dose is necessary. There are no known specific symptoms of dantrolene sodium overdose. Caution is required if there are any signs of hyperkalaemia.

If you stop using Dantrium IV

If it should appear necessary to discontinue Dantrium IV therapy, intensive care and supportive therapeutic measures which have been initiated should be continued on an individual basis.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects were observed:

Unknown (Frequency cannot be estimated from the available data):

muscle weakness, tiredness, dizziness, headache, gastrointestinal complaints such as nausea, vomiting, diarrhoea, anaphylaxis, allergic reactions, mostly of the skin, as well as thrombophlebitis or reactions at the application site, somnolence, convulsion, speech disorder, bradycardia (slowed heartbeat), tachycardia (accelerated heartbeat), pleural effusion (fluid collection in the chest), respiratory failure, abdominal pain, gastrointestinal bleeding, jaundice, hepatitis, hyperhidrosis (increased sweat secretion), crystalluria (accumulation of crystals in urine sediment), heart failure.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Dantrium IV

Keep out of the sight and reach of children. Do not store Dantrium IV above 25°C.

The solution for injection should be stored between 15 and 25°C, not be refrigerated or frozen, protected from direct light and used within 6 hours of being made up.

Do not use Dantrium IV after the expiry “EXP” date which is stated on the label.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Contents of the pack and other information
What Dantrium IV contains:
  • The active substance is dantrolene sodium 20 mg.
  • The other ingredients are mannitol and sodium hydroxide.

What Dantrium IV looks like and contents of the pack

The product is a pale orange-yellow powder for solution for injection, supplied to hospitals in packs of 12 and 36 glass vials. Not all pack sizes may be marketed. Each vial is provided with a single use filtration device.

Marketing Authorisation Holder:
Norgine Pharmaceuticals Limited
Norgine House
Widerwater Place
Moorhall Road
Harefield
Uxbridge
UB9 6NS
UK

Manufacturer
Norgine BV
Antonio Vivaldistraat 150
1083 HP Amsterdam
The Netherlands

If you need the information on this leaflet in an alternative format such as large print, please ring from the UK 0800 198 5000.

This leaflet was last revised in April 2022.

Norgine Limited
Company image
Address
Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS
Telephone
+44 (0) 1895 826 606
Medical Information e-mail
[email protected]
Stock Availability
[email protected]